US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
SDEV
$7.48
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
SDEV
$7.48
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Jaguar Health, Inc. - Common Stock
(NQ:
JAGX
)
3.660
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jaguar Health, Inc. - Common Stock
< Previous
1
2
...
18
19
20
21
22
23
24
25
Next >
We Asked, You Answered: What Stock Would You Never Buy Again?
↗
May 02, 2022
Almost all traders have had that moment: A confident stock pick or strategy that backfires and leaves the investor with less money than they had before and vowing never to trade that stock again.
Via
Benzinga
Jaguar Health, Inc. (NASDAQ: JAGX) Featured in Coverage of NobleCon18
April 27, 2022
Via
Investor Brand Network
Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
April 27, 2022
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / April 27, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health to Present at the NobleCon18 Investor Conference on April 21, 2022
April 20, 2022
SAN FRANCISCO, CA / ACCESSWIRE / April 20, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, Jaguar's president, founder, and CEO, will present at NobleCon18 - Noble Capital...
From
Jaguar Health, Inc.
Via
AccessWire
Why Is Jaguar Health (JAGX) Stock Up Today?
↗
March 31, 2022
Here's the big partnership news that's taking shares of Jaguar Health and JAGX stock soaring in afternoon trading today.
Via
InvestorPlace
Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)
April 15, 2022
SAN FRANCISCO, CA / ACCESSWIRE / April 15, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's New Employee Inducement Award Plan (the "Inducement...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About Chemotherapy-Induced Diarrhea (CID) in Dogs on April 12th, the Final Day of the Veterinary Cancer Society (VCS) Mid-Year Conference in Puerto Vallarta, Mexico
April 06, 2022
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA Veterinary...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Announces Appointment of Pravin Chaturvedi, Ph.D., as Chief Scientific Officer
April 05, 2022
Dr. Chaturvedi continues to serve as Chair of company's Scientific Advisory Board Dr. Chaturvedi continues to provide leadership to the development of two crofelemer pipeline indications, with...
From
Jaguar Health, Inc.
Via
AccessWire
Here's Why Jaguar Health Shares Are Rising
↗
April 04, 2022
Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 10.90% at $0.70 on continued momentum after the company last week announced an agreement granting Quadri Pharmaceuticals for exclusive...
Via
Benzinga
53 Biggest Movers From Yesterday
↗
April 01, 2022
Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing...
Via
Benzinga
Here's Why Jaguar Health Shares Are Popping Off
↗
March 31, 2022
Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 31.2% at $0.70 after the company announced an agreement granting Quadri Pharmaceuticals for exclusive promotional, commercialization and...
Via
Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
↗
March 31, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
March 31, 2022
Rise and shine, trader! We're getting ready for another busy day of trading with the biggest pre-market stock movers for Thursday!
Via
InvestorPlace
Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets
March 31, 2022
Agreement grants Quadri Pharmaceuticals Store exclusive promotional, commercialization, and distribution rights in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates, and Oman for human...
From
Jaguar Health, Inc.
Via
AccessWire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
March 16, 2022
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 114.0% to $0.59 during Wednesday's regular session. As of 13:30 EST, this security is trading at a volume of...
Via
Benzinga
80 Biggest Movers From Yesterday
↗
March 17, 2022
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares gained 86.7% to close at $0.5150 on Wednesday after the company announced FDA clearance of its IND for SON-...
Via
Benzinga
Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast
March 14, 2022
Click here to access webcast replay Core 2022 development initiatives: - Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea...
From
Jaguar Health, Inc.
Via
AccessWire
68 Biggest Movers From Yesterday
↗
March 16, 2022
Gainers Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
March 14, 2022
Welcome back! I hope you're recharged from the weekend break because we've got the biggest pre-market stock movers to start Monday with!
Via
InvestorPlace
Jaguar Health Provides Company Updates and Reports 2021 Financials
March 11, 2022
Core 2022 development initiatives: - Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) - Initiation and completion in...
From
Jaguar Health, Inc.
Via
AccessWire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
March 11, 2022
Gainers CVRx (NASDAQ:CVRX) shares rose 11.6% to $7.2 during Friday's after-market session. The market value of their outstanding shares is at $156.2 million.
Via
Benzinga
Jaguar Health's Earnings: A Preview
↗
March 11, 2022
Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates
March 07, 2022
Click here to register for webcast Company plans to file its Annual Report on March 11, 2022 on Form 10-K for the fiscal year ended December 31, 2021 SAN FRANCISCO, CA / ACCESSWIRE / March 7, 2022 /...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas
March 01, 2022
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA U.S. veterinarians,...
From
Jaguar Health, Inc.
Via
AccessWire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
February 25, 2022
Gainers Surgalign Holdings (NASDAQ:SRGA) ...
Via
Benzinga
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
February 16, 2022
In December of 2021, FDA conditionally approved Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency
February 15, 2022
SME status is an important designation for Italy-based Napo Therapeutics' rare/orphan disease business model SAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / February 15, 2022 / Jaguar Health...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
February 10, 2022
Canalevia™ would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea SAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX),...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)
February 01, 2022
Study results expected to be described in upcoming presentations and publications CDD patients face intestinal failure (IF), similar to patients suffering from short bowel syndrome (SBS) - the priority...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics
January 24, 2022
Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases - beginning with short bowel syndrome (SBS) For SBS, Napo Therapeutics has...
From
Jaguar Health, Inc.
Via
AccessWire
< Previous
1
2
...
18
19
20
21
22
23
24
25
Next >
